share_log

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

regenxbio的股票在公司宣佈對其杜氏肌營養不良症基因治療的關鍵試驗首次給藥後上漲。
Benzinga ·  11/18 20:18

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

regenxbio的股票在公司宣佈給其杜氏肌營養不良基因療法的首名患者注射後上漲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論